Haekyung Jeon-Slaughter1. 1. Department of Psychiatry and Behavioral Sciences, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. hattie-jeon-slaughter@ouhsc.edu
Abstract
PURPOSE: Patients' nonadherence to antidepressant treatment hampers cost and efficacy of depression-specific treatment. However, previous studies have failed to find consistent findings in economic effect on nonadherence and also failed to reach consensus in how to measure nonadherence to treatment. The study attempts to investigate income effect on nonadherence to selective serotonin reuptake inhibitors (SSRIs) treatment with clear definitions of nonadherence: self discontinuation of SSRIs (nonpersistence) and under-dose of SSRIs (noncompliance). METHODS: The study extracted data from the National Comorbidity Survey-Replication (NCS-R). The study sample (n = 280) includes adults between the ages of 18 and 64 who were diagnosed with Diagnostic Statistics Manual IV Major Depressive Episode (MDE) at some point during their lifetime and medicated with SSRIs in the past 12 months. RESULTS: Just above poverty level of family income and no health insurance increased the risk of medication nonpersistence in SSRIs treatment. The study findings confirmed that African Americans were at higher risk of medication noncompliance than Whites (odds ratio, 4.53) and MDE comorbidity was positively associated with medication noncompliance (odds ratio, 4.25). CONCLUSIONS: Low income level, combined with health insurance status, and race/ethnicity, predict nonadherence to antidepressant treatment. The study findings would help physicians and hospitals developing interventional strategies and programs to increase patients' adherence rates in antidepressant treatment.
PURPOSE:Patients' nonadherence to antidepressant treatment hampers cost and efficacy of depression-specific treatment. However, previous studies have failed to find consistent findings in economic effect on nonadherence and also failed to reach consensus in how to measure nonadherence to treatment. The study attempts to investigate income effect on nonadherence to selective serotonin reuptake inhibitors (SSRIs) treatment with clear definitions of nonadherence: self discontinuation of SSRIs (nonpersistence) and under-dose of SSRIs (noncompliance). METHODS: The study extracted data from the National Comorbidity Survey-Replication (NCS-R). The study sample (n = 280) includes adults between the ages of 18 and 64 who were diagnosed with Diagnostic Statistics Manual IV Major Depressive Episode (MDE) at some point during their lifetime and medicated with SSRIs in the past 12 months. RESULTS: Just above poverty level of family income and no health insurance increased the risk of medication nonpersistence in SSRIs treatment. The study findings confirmed that African Americans were at higher risk of medication noncompliance than Whites (odds ratio, 4.53) and MDE comorbidity was positively associated with medication noncompliance (odds ratio, 4.25). CONCLUSIONS: Low income level, combined with health insurance status, and race/ethnicity, predict nonadherence to antidepressant treatment. The study findings would help physicians and hospitals developing interventional strategies and programs to increase patients' adherence rates in antidepressant treatment.
Authors: Christopher Ron Cantrell; Michael T Eaddy; Manan B Shah; Timothy S Regan; Michael C Sokol Journal: Med Care Date: 2006-04 Impact factor: 2.983
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Tarja K Melartin; Heikki J Rytsälä; Ulla S Leskelä; Paula S Lestelä-Mielonen; T Petteri Sokero; Erkki T Isometsä Journal: J Clin Psychiatry Date: 2005-02 Impact factor: 4.384
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Aruna S Rao; Ann I Scher; Rebeca V A Vieira; Kathleen R Merikangas; Andrea L Metti; B Lee Peterlin Journal: Headache Date: 2015-10-16 Impact factor: 5.887
Authors: Daniel V Vigo; Alan E Kazdin; Nancy A Sampson; Irving Hwang; Jordi Alonso; Laura Helena Andrade; Olatunde Ayinde; Guilherme Borges; Ronny Bruffaerts; Brendan Bunting; Giovanni de Girolamo; Silvia Florescu; Oye Gureje; Josep Maria Haro; Meredith G Harris; Elie G Karam; Georges Karam; Viviane Kovess-Masfety; Sing Lee; Fernando Navarro-Mateu; José Posada-Villa; Kate Scott; Juan Carlos Stagnaro; Margreet Ten Have; Chi-Shin Wu; Miguel Xavier; Ronald C Kessler Journal: Int J Ment Health Syst Date: 2022-06-23
Authors: Daniel Vigo; Josep Maria Haro; Irving Hwang; Sergio Aguilar-Gaxiola; Jordi Alonso; Guilherme Borges; Ronny Bruffaerts; Jose Miguel Caldas-de-Almeida; Giovanni de Girolamo; Silvia Florescu; Oye Gureje; Elie Karam; Georges Karam; Viviane Kovess-Masfety; Sing Lee; Fernando Navarro-Mateu; Akin Ojagbemi; Jose Posada-Villa; Nancy A Sampson; Kate Scott; Juan Carlos Stagnaro; Margreet Ten Have; Maria Carmen Viana; Chi-Shin Wu; Somnath Chatterji; Pim Cuijpers; Graham Thornicroft; Ronald C Kessler Journal: Psychol Med Date: 2020-10-20 Impact factor: 10.592